| Particulars (Rupees in Crores.) | Mar-2025 | Dec-2024 | Sept-2024 | Jun-2024 | Mar-2024 |
|---|---|---|---|---|---|
Gross Sales | 1,018 | 943.7 | 891 | 789.7 | 916.9 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,018 | 943.7 | 891 | 789.7 | 916.9 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 18.9 | 18.3 | 16.5 | 50.1 | 16.1 |
Total Income | 1,036.9 | 962 | 907.5 | 839.8 | 933 |
Total Expenditure | 674.4 | 660.1 | 646.2 | 619.9 | 600 |
PBIDT | 362.5 | 301.9 | 261.3 | 219.9 | 333 |
Interest | 15.9 | 12.4 | 13.1 | 11.7 | 12.9 |
PBDT | 346.6 | 289.5 | 248.2 | 208.2 | 320.1 |
Depreciation | 106.1 | 108.7 | 110.9 | 106.9 | 111.1 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 46.9 | 44.9 | 27.4 | 19.2 | 42.4 |
Deferred Tax | 10.3 | 4.8 | 3.8 | 6.4 | -22 |
Reported Profit After Tax | 183.3 | 131.1 | 106.1 | 75.7 | 188.6 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 183.3 | 131.1 | 106.1 | 75.7 | 188.6 |
Extra-ordinary Items | 0 | 0 | 0 | 23.91 | 0 |
Adjusted Profit After Extra-ordinary item | 183.3 | 131.1 | 106.1 | 51.79 | 188.6 |
EPS (Unit Curr.) | 4.56 | 3.27 | 2.64 | 1.89 | 4.7 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 402.5 | 402.5 | 402.5 | 402.5 | 402 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 35.6 | 31.99 | 29.32 | 27.84 | 36.31 |
PBDTM(%) | 34.04 | 30.67 | 27.85 | 26.36 | 34.91 |
PATM(%) | 18 | 13.89 | 11.9 | 9.58 | 20.56 |
The purchase is anticipated to enhance Syngene's position in the biologics contract development and manufacturing organization (CDMO) arena, specifically in the US market.
The company reported an operating EBITDA of ₹343.60 Crore in the quarter four of FY25. It registered a growth of 8.4% on a year-on-year basis.
This acquisition will also augment Syngene’s biologics capabilities and further strengthen its global presence.
The company's revenue from operations also grew healthily, up by 10.6% YoY to ₹943 crore, as against ₹853.5 crore in Q3 FY24.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
